TY - JOUR JO - EuroIntervention TI - First-in-man use of the new-generation TriGUARD 3 cerebral embolic protection device during transcatheter aortic valve implantation AB - <p class="text-1er-paragraph">J. Rodés-Cabau holds the Canadian Research Chair “Fondation Famille Jacques Larivière” for the Development of Structural Heart Disease Interventions and has received institutional research grants from Edwards Lifesciences, Medtronic and Heart Leaflet Technologies. T. Nazif is an investigator for the TriGUARD 3 US trial. The other author has no conflicts of interest to declare.</p> AU - Paradis Jean-Michel AU - Nazif M. Tamim AU - Rodés-Cabau Josep VL - 14 IS - 11 Y1 - 07/12/2018 Y1 - 2018 DOI - 10.4244/EIJ-D-18-00442 SP - e1178 EP - e1179 PB - Europa Digital & Publishing SE - INTERVENTIONS FOR VALVULAR DISEASE AND HEART FAILURE UR - https://eurointervention.pcronline.com/article/first-in-man-use-of-the-new-generation-triguard-3-cerebral-embolic-protection-device-during-transcatheter-aortic-valve-implantation SN - 1774-024X ER -